Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: tocilizumab

In the Thick of It: Scleroderma Update 2021

Jason Liebowitz, MD, FACR  |  December 2, 2021

Laura Hummers, MD, MSc, provided an update on the extra-pulmonary manifestations of scleroderma & the best ways to approach management of these issues.

Filed under:ACR ConvergenceConditionsMeeting ReportsSystemic Sclerosis Tagged with:ACR Convergence 2021

Joint Venture: 2021 Updates in Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  November 24, 2021

An update on the state of RA management was presented by Dr. Bryant England, a co-author of the 2021 ACR Guideline on the Management of Rheumatoid Arthrits, during the Review Course held during ACR Convergence 2021.

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2021ACR Convergence 2021 – RA

Research Helps Explain Idiosyncrasies of COVID-19

Jason Liebowitz, MD, FACR  |  November 23, 2021

The Basic and Clinical Research Conference session on Rheumatology Complications of Emerging Viral Infections/SARS-CoV-2 presented findings from numerous studies that help explain some of the idiosyncrasies of COVID-19.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2021COVID-19interferonMultisystem Inflammatory Syndrome in Children (MIS-C)

The 2021 ARP President’s Awards & Merit Awards

Patrice Fusillo  |  November 14, 2021

During ACR Convergence 2021 in early November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the winners of the ARP President’s and Merit Awards. ARP PRESIDENT’S AWARDS The ARP president can choose to honor ACR/ARP…

Filed under:ACR ConvergenceAwardsMeeting Reports Tagged with:ACR Convergence 2021Association of Rheumatology Professionals (ARP)Daniel SchafferDr. Becki ClevelandDr. Catherine BackmanDr. Debbie Ehrmann-FeldmanDr. Emily C. SomersDr. Jill BlitzDr. Kamala NolaDr. Marian T. HannanDr. Monique GignacDr. Susan MurphyLinda RodamakerNorma Liburd

Case Report: Rheumatoid Arthritis Complicated by Large Granular Lymphocytic Leukemia

Nam D. Nguyen, DO (Maj., USAF, MC), Erica Hill, DO (Lt. Col., USAF, MC), & Jay Higgs, MD (Col. [ret], USAF, MC)  |  November 14, 2021

Large granular lymphocytic (LGL) leukemia is a rare, chronic, lymphoproliferative disorder of cytotoxic T cell or natural killer cell lineage with an annual incidence of 0.72 cases per 1 million people in the U.S.1 The most common sub­type of LGL leukemia, T-LGL leukemia, follows an indolent disease course and accounts for approximately 85% of cases….

Filed under:ConditionsRheumatoid Arthritis Tagged with:large granular lymphocyte leukemiavertebral fracture

Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

Ashraf Raslan, MD, Dorian Infantino, MD, Roman Zuckerman, DO, & Daniel Berlin, MD  |  November 14, 2021

Giant cell arteritis (GCA) is a granulomatous vasculitis of large- and medium-sized arteries, usually affecting the cranial branches of the aortic arch. It is the most common vasculitis, with the highest risk factor being age. Accurate diagnosis and prompt initiation of therapy are of great importance to prevent serious complications, with the most feared being…

Filed under:ConditionsVasculitis Tagged with:case reportGiant Cell Arteritistocilizumab

From Contraception to Breastfeeding: Experts Address Reproductive Health & Medication Management

Mithu Maheswaranathan, MD  |  November 11, 2021

ACR CONVERGENCE 2021—Rheumatologists are often left in a challenging space when managing medications for patients with rheumatic diseases in relation to contraception, pregnancy and breastfeeding, especially with many novel immunosuppressants and often a dearth of pregnancy safety data. On Nov. 6 during ACR Convergence 2021, leading reproductive health experts came together to speak on this…

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2021breastfeedingcontraceptivepregnancyreproductive health

Vasculitis Guidelines in Focus, Part 5: Takayasu Arteritis

Michael Putman, MD  |  October 11, 2021

Andy Abril, MD, a lead author of the ACR/VF guideline for Takayasu arteritis (TAK), discusses the recommendations for TAK.

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:guidelineTakayasu arteritis (TAK)VasculitisVasculitis Foundation

A Look Back at the ACR’s Strong Response to COVID-19

David R. Karp, MD, PhD  |  September 14, 2021

We are now a year-and-a-half into the COVID‑19 pandemic, and rheuma­tologists and rheuma­tology professionals are still facing some of the same challenges that began in spring 2020, as well as new ones. Most recently, we learned that COVID‑19 vaccine efficacy is reduced in some patients on immunosuppressive therapies and the need for additional immunization is…

Filed under:ConditionsLegislation & AdvocacyPediatric ConditionsProfessional Topics Tagged with:COVID-19Hydroxychloroquine (HCQ)Multisystem Inflammatory Syndrome in Children (MIS-C)President's Perspectivetelehealth

20 Years of RA Data: First-Line Biologic & Targeted Synthetic DMARD Trends

Michele B. Kaufman, PharmD, BCGP  |  September 1, 2021

Data from a single-center registry shines light on 20 years of trends in first-line, biologic disease-modifying anti-rheumatic drug prescriptions for patients with rheumatoid arthritis.

Filed under:Biologics/DMARDsDrug Updates Tagged with:biologic drugsEULARRheumatoid Arthritis (RA)trends

  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 30
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences